Oncology Brothers: Practice-Changing Cancer Discussions cover image

GI Cancer ESMO 2025 Highlights: DYNAMIC-III, PEGASUS, STELLAR-303, MATTERHORN, FORTITUDE-101

Oncology Brothers: Practice-Changing Cancer Discussions

00:00

STELLAR-303: IO plus TKI shows OS benefit

Rachna explains STELLAR-303: atezolizumab plus zenzolitinib improved OS/PFS in refractory MSS CRC but with high grade‑3 toxicities.

Play episode from 06:48
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app